Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2746-2757

  Agarwal, Anika ^a   Covic, Lidija ^a   Sevigny, Leila M ^a   Kaneider, Nicole C ^a   Lazarides, Katherine ^a   Azabdaftari, Gissou ^a   Sharifi, Sheida ^a,b   Kuliopulos, Athan ^a,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT AUBURN HOSPITAL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGENASE INHIBITOR; DOCETAXEL; FN 439; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; P 1PAL 7; PROTEINASE ACTIVATED RECEPTOR 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CARCINOMA CELL; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; BODY FLUIDS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; HUMANS; METALLOPROTEASES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NIH 3T3 CELLS; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PERITONEUM; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54049128201     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0177     Document Type: Article

References (50)

1. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24.
2. Sawiris GP, Sherman-Baust CA, Becker KG, Cheadle C, Teichberg D, Morin PJ. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 2002;62:2923-8.
3. Conrads TP, Fusaro VA, Ross S, et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 2004;11:163-78.
4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
5. Pei D. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell 2005;7:207-8.
6. Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 1994;58:50-6.
7. Fishman D, Bafetti LM, Banionis S, Kearns AS, Chilukuri K, Stack MS. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 1997;80:1457-1463.
8. Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS, Mok SC. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 2000;77:369-376.
9. Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, Fishman DA. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 2004;64:7045-9.
10. Lengyel E, Schmalfeldta B, Konika E, et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001;82:291-8.
11. Huang S, Arsdall MV, Tedjarati S, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002;94:1134-42.
12. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-2.
13. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-61.
14. van't Veer LJ, Dai H, Vijver MJvd, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
15. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J, Lefall LD. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005;11:481-3.
16. Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58:5321-5.
17. Six L, Grimm C, Leodolter S, et al. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. Gynecol Oncol 2006;100:506-10.
18. Boire A, Covic L, Agarwal A, Jacques S, Sharifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005;120:303-13.
19. Arora P, Ricks TK, Trejo J. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci 2007;120:921-8.
20. Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998;4:909-14.
21. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer 2005;113:372-8.
22. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci U S A 2002a;99:643-8.
23. Sanceau J, Truchet S, Bauvois B. Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells. J Biol Chem 2003;278:36537-46.
24. Ueda J, Kajita M, Suenga N, Fujii K, Seiki M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 2003;22:8716-22.
25. Kuliopulos A, Walsh CT. Production, purification, and cleavage of tandem repeats of recombinant peptides. J Am Chem Soc 1994;116:4599-607.
26. Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med 2005;11:661-5.
27. Kamath L, Meydani A, Foss F, Kuliopulos A. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res 2001;61:5933-40.
28. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 1999;38:4572-85.
29. Albini A, Benelli R. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protocols 2007;2:504-11.
30. Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based intervention of thrombin receptor signaling and systemic platelet activation. Nat Med 2002b;8:1161-5.
31. Leger A, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 2006;113:1244-54.
32. Covic L, Tchernychev B, Jacques S, Kuliopulos A. In: Pharmacology and in vivo efficacy of pepducins in hemostasis and arterial thrombosis. Langel U, editor. New York: Taylor & Francis; 2006. p. 245-57.
33. Andrade-Gordon P, Maryanoff BE, Derian CK, et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A 1999;96:12257-62.
34. Nguyen N, Kuliopulos A, Graham RA, Covic L. Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloprotease-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res 2006;66:2658-65.
35. Davidson B, Goldberg I, Gotlieb WH, Ben-Baruch G, Nesland JM, Reich R. The prognostic value of metalloproteinase and angiogenic factors in ovarian cancer. Mol Cell Endocrinol 2002;187:39-45.
36. Drew AF, Blick TJ, Lafleur MA, et al. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice. Gynecol Onc 2004;95:437-48.
37. Cao J, Rehemtulla A, Bahou W, Zucker S. Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J Biol Chem 1996;271:30174-80.
38. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
39. Wang P, Nie J, Pei D. The hemopexin domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) Is not required for its activation of proMMP2 on cell surface but is essential for MT1-MMP-mediated invasion in three-dimensional type I collagen. J Biol Chem 2004;279:51148-55.
40. Murphy G, Knauper V, Cowell S, et al. Evaluation of some newer matrix metalloproteinases. Ann NY Acad Sci 1999;878:25-39.
41. Nagy JA, Masse EM, Herzberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;55:360-8.
42. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer. Am J Pathol 1998;153:1249-56.
43. Garcia JG, Davis HW, Patterson CE. Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. J Cell Physiol 1995;163:510-22.
44. Klarenbach SW, Chipiuk A, Nelson RC, Hollenberg MD, Murray AG. Differential actions of PAR2 and PAR1 in stimulating human endothelial cell exocytosis and permeability: the role of Rho-GTPases. Circ Res 2003;92:272-8.
45. Kaneider NC, Leger AJ, Agarwal A, et al. Role reversal for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007;8:1303-12.
46. Goerge T, Barg A, Schnaeker E-M, et al. Tumor-derived matrix metalloprotease-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 2006;66:7766-74.
47. Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005;11:2686-94.
48. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
49. Hotary K, Li X-Y, Allen E, Stevens SL, Weiss SJ. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 2006;20:2673-86.
50. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.